APP and Alzheimer disease: Concerning in vivo studies, TUDCA significantly attenuates amyloid-β deposition in the brain and decreases amyloid-β 1–40 and 1–42 levels in transgenic APP/PS1 AD mice, suggesting reduced amyloidogenic production [41].